Imprivata
Imprivata Company Growth, Stability & Outlook
Imprivata Employee Reviews
What People Are Saying About Imprivata
-
Strong Revenue Growth: Recent credit analysis highlights low-teen percentage growth in ARR and ACV since 2022, with projections for continued top-line expansion. Healthcare cybersecurity tailwinds and ongoing adoption on platforms like Azure support this momentum.
-
Healthy Cash Flow: An S&P upgrade in late 2025 cites improving cash flow with leverage expected to trend down through 2026. This points to stronger cash generation underpinning measured growth investments.
-
Product Line Growth: The October 2025 Verosint acquisition added AI-powered identity threat detection and risk signaling to the platform, broadening use cases. Continued Azure-aligned releases and clinical workflow enhancements indicate an expanding solution suite.
